Year All20242023202220212020201920182017201620152014 Jan 04, 2021 Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Dec 11, 2020 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Nov 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results Nov 03, 2020 Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome Oct 29, 2020 Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting Sep 30, 2020 Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome Sep 15, 2020 Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Aug 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results Jun 29, 2020 Soleno Therapeutics Added to Russell 3000® Index Jun 26, 2020 Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jan 04, 2021 Soleno Therapeutics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Dec 11, 2020 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
Nov 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
Nov 03, 2020 Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome
Oct 29, 2020 Soleno Therapeutics Announces Late-Breaking Oral Presentation with Body Composition Results from Phase III DESTINY PWS Trial of DCCR in Prader-Willi Syndrome at ObesityWeek® 2020 Meeting
Sep 30, 2020 Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome
Sep 15, 2020 Soleno Therapeutics to Participate in Fireside Chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aug 10, 2020 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2020 Financial Results
Jun 26, 2020 Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters’ Option to Purchase Additional Shares